Introducing RUXIENCE

RUXIENCE is a biosimilar* to Rituxan® (rituximab) that was approved by the FDA based on the totality of evidence1,2

RUXIENCE offers the potential to help address treatment costs and shows no clinically meaningful differences to Rituxan1-3

Clinical Information